Followers | 20 |
Posts | 5340 |
Boards Moderated | 0 |
Alias Born | 01/04/2012 |
Tuesday, October 17, 2017 8:04:18 AM
The Fly
In my opinion, the offer will depend on whether Ani is accelerating the next step to get ready for a future co-promotion deal with AbbVie or if Abbvie is triggering the deal.
If we are looking at the next step you will see a company with a global sales force. Just like the BPAX - ANI deal, announcement regarding Libigel will not be made and we can expect to get shares in the acquiring company. Unlike the BPAX-ANI deal, where most shares were held by retail investors, ANI's shares are heavily owned by institutional investors more likely to vote with the BOD's recommendation. Sadly, had we known the full picture with the BAX-ANIP merger we may have taken the first offer. In the end BPAX shareholder's walked away with 43% of the merged company as opposed to 47%.
If on the other hand AbbVie is going for the whole enchilada and looking at a full buyout. It could be sizable. I believe Abbott labs influenced the clinical trial changes in November 2009 which led to the discoveries. If so they would be entitle to discount over another bidder coming off the street. Given that Abbvie paid $21 billion for Imbruvica a drug estimated to generate peak sales of $7 billion if all indications are approved. However Imbruvica was already on the market and on the way to reaching Blockbuster status. If the employee I spoke with was right all the indications for Libigel if approved is estimated to generate peak sales in excess $16 billion. Now this would have to be discounted for Abbvie's early collaboration and taking over the second part of the safety/efficacy study, in addition to the fact it is not approved yet. They are gaining ANI's manufacturing facilities,and pipeline.
Think about it, if as I suspect Abbvie was willing to pay $350 million for a Priority Review Voucher which in my opinion will be used for Libigel, a $12 billion, maybe more much for a buyout from AbbVie is not unreasonable.
I believe the reason for all the non-disclosure was BPAX wanted more than Abbott/AbbVie were willing to offer at the time. However AbbVie did not want the discoveries becoming public knowledge. Which could have made a buyout much more expensive when and if they decided to pull the trigger.
Recent ANIP News
- ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences • GlobeNewswire Inc. • 05/01/2024 08:30:00 PM
- ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET • GlobeNewswire Inc. • 04/18/2024 08:05:00 PM
- ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension • GlobeNewswire Inc. • 04/09/2024 10:50:00 AM
- ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis • GlobeNewswire Inc. • 04/04/2024 10:50:00 AM
- ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium • GlobeNewswire Inc. • 04/03/2024 10:50:00 AM
- ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP • GlobeNewswire Inc. • 03/27/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 12:25:12 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 10:59:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:26:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:42:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:21:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:16:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 02:11:59 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/07/2024 09:05:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 10:58:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 10:31:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 09:29:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:24:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 10:00:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 12:18:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:18:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:12:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:09:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:06:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:03:56 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM